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ABSTRACT
Despite catecholamines being lifesaving 
drugs, they can also be harmful. Adrenergic 
overload is one of the major promoters of 
supra- and ventricular arrhythmias, which 
induce hemodynamic instability in the crit-
ically ill. In this paper we will focus on the 
pathophysiology of atrial fibrillation (AF), 
the importance of adrenergic overload for 
triggering AF, the importance of the auto-
nomic nervous system and finally, we will 
challenge the importance of decreasing 
adrenergic load with selective and non-
selective β-blockers, which have different 
effects on the metabolism in  the severely 
ill.  We will also emphasize the importance 
of an individual approach due to pharma-
cogenetic differences in β-adrenergic sig-
nalling.  
Key word: catecholamine, atrial fibrillation, 
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INTRODUCTION
Atrial fibrillation (AF) is a supraventricu-
lar tachycardia characterized electrically 
by chaotic atrial activation that results in 
mechanically ineffective atrial contraction. 
New-onset AF is a very  common arrhyth-
mic complication of critical illness, with in-
cidence that varies from 4 to 9% in general 
intensive care unit patients, to 32 to 50% in 
patients after major cardiac and thoracic 
surgery. ( - )
New-onset AF is associated with increased 
morbidity and mortality  in patients who 
are hospitalized for heart failure, as well as 
various other critical conditions, although 
it is possible that AF in these cases is pri-
marily a marker of disease severity rather 
than a direct cause of death. ( , )
AF is associated with cardioembolic events 
and heart failure, longer hospital stays, and 
reduced quality of life as well as a two- to 
fivefold increased mortality. ( - )
AF in critically ill patients can present as 
asymptomatic ECG changes or, on the oth-
er hand, it can cause severe hemodynamic 
instability with profound hypotension, 
myocardial ischemia, heart failure leading 
to pulmonary edema, cardiogenic shock 
with subsequent tissue hypoxia and organ 
dysfunction. Highly symptomatic patients 
are candidates for synchronized electro-
cardioversion. ( )
Despite catecholamines being lifesaving 
drugs, they can also be harmful. Adrener-
gic overload is one of the major promoters 
of hemodynamic instability due to supra- 
and ventricular arrhythmias. In this paper 
we will focus on the pathophysiology of AF, 
the importance of adrenergic overload for 
triggering AF, the importance of the auto-
nomic nervous system and finally, we will 
challenge the importance of decreasing the 
adrenergic load. We will also emphasize 
the importance of an individual approach 
due to pharmacogenetic differences in 
β-adrenergic signaling. Catecholamines 
also have other non-cardiovascular ef-
fects, i.e. they have profound metabolic ef-
fects, elevating resting energy expenditure 
and changing substrate oxidation rates. At 
the end, we will discuss possible pathways 
and effects of selective and non-selective 
β-blockers on hyper- metabolism of the 
severely ill.  
PATHOPHYSIOLOGY OF AF
Structural and electrical atrial remodeling 
are fundamental mechanisms for AF. ( ) 
The majority of critically ill patients have 
already acquired some structural and 
electrical atrial remodeling before Inten-
sive care unit (ICU) admission. Structural 
remodeling, particularly fibrosis, is the 
mainstay in many forms of AF. This fi-
brosis is primarily due to atrial dilatation, 
which leads to local activation of the renin 
aldosterone angiotensin system (RAAS) 
and further initiates multiple cell signal-
ing cascades, including inflammation and 
apoptosis, stimulating fibrosis, as well as 
possible modulation of ion channels and 
gap-junction dynamics. ( ) Fibroblasts can 
couple electrically to cardiomyocytes and 
when increased in number, promote re-
entry and/or ectopic activity. ( ) 
Electrical remodeling promotes AF by act-
ing on the fundamental arrhythmia mech-
anism: focal ectopic activity and reentry. 
In this context two principles have gained 
attention: factors triggering the onset and 
factors perpetuating AF. (11)
Ectopic focal discharges often initiate AF. 
Rapidly firing foci initiating paroxysmal 
AF arise most commonly from the atrial 
myocardial sleeves that extend into pul-
monary veins. ( ) Although the pulmo-
nary veins are the most common sites for 
ectopic focal triggers, they can also arise 
elsewhere, including the posterior LA (left 
atrium), ligament of  Marshall, coronary 
sinus, venae cavae, septum, and append-
ages.  Atrial myocardial fibers are oriented 
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in disparate directions, and possess unique 
anatomical and electrophysiological fea-
tures for their arrhythmogenic nature. 
The relatively depolarized resting poten-
tials in pulmonary vein myocytes promote 
sodium channel inactivation and to the 
abrupt changes in fiber orientation and 
thus favors reentry. These myocytes also 
demonstrate abnormal automaticity and 
triggered activity that could promote rapid 
focal firing. (11)
The evolution of AF from paroxysmal to 
persistent to permanent forms, through 
atrial remodeling, can be caused by the 
arrhythmia itself and/or progression of 
underlying heart disease. Atrial electri-
cal properties are modified by affecting 
expression and function of ion-channels, 
pumps, and exchangers, thus a reentry 
prone substrate is created which pro-
motes arrhythmia. This concept is known 
as atrial remodeling and was first tested 
in animal models showing that long-term 
rapid atrial pacing or maintenance of AF 
favors the occurrence and maintenance of 
AF (‘AF Begets AF’). ( ) The developments 
of functional reentry substrates, which are 
reversible on AF termination, contribute 
to persistent AF. 
There are more potential mechanisms for 
ectopic triggering. The resting potential of 
a normal atrial cell is maintained by high 
resting K+ permeability through the in-
ward rectifier K+ current (IK1). Although 
normal human atrial cells also manifest 
pacemaker current (If ), it is overwhelmed 
by much larger IK1, and does not manifest 
automaticity. Enhanced automaticity
is caused by changes in this balance re-
sulting from decreased (IK1) and/ or en-
hanced (If). ( )
Early after depolarizations (EAD) involve 
abnormal secondary cell membrane de-
polarization during repolarization phases. 
EAD are caused mainly by action poten-
tial duration prolongation (i.e. congenital 
long QT-Syndrome). ( ) This allows L-type 
Ca2+ current (ICaL) to recover from inac-
tivation, leading to inward movement of 
Ca2+ ions causing EAD.
Delayed after depolarizations (DAD) are 
caused by abnormal diastolic release of 
Ca2+ from sarcoplasmic reticulum stores. 
Specialized sarcoplasmic reticulum Ca2+ 
channels (called ryanodine receptors 
[RyRs]) release Ca2+ in response to trans-
membrane Ca2+ entry. (11) RyRs are nor-
mally closed during diastole but can open 
if they are functionally defective or if the 
sarcoplasmic reticulum is Ca2+ overload-
ed. When one Ca2+ ion is released during 
diastole, it is exchanged for three extra-
cellular Na+ ions by the Na+- Ca2+ ex-
changer, causing a net depolarizing inward 
positive-ion movement (called transient 
inward current [Iti]) that underlies DADs. 
Congestive heart failure, one of the most 
common causes of AF, produces atrial cell 
Ca2+ overload and DADs. ( )
Effects of the Autonomic Nervous System 
Parasympathetic stimulation causes vagal 
discharge which enhances acetylcholine 
dependent K+ current (IKACh), reduc-
ing atrial action potential duration and 
refractoriness, increasing the susceptibility 
to reentry mechanism. (11) Sympathetic 
stimulation causes β-adrenoceptor (AR) 
activation increases diastolic Ca2+ leak 
and promotes DAD by hyperphosphoryl-
ating RyR2s, which promotes automaticity 
and triggered activity. Atrial sympathetic 
hyperinnervation
occurs in persistent AF patients. ( ) Auto-
nomic neural remodeling contributes to 
positive feedback loops that promote AF 
persistence and recurrence. Plexi of auto-
nomic ganglia that constitute the intrinsic 
cardiac autonomic nervous system are lo-
cated in epicardial fat near the pulmonary 
vein-LA junctions, at the orifices of venae 
cavae in the right atrium and the ligament 
of Marshall. The AF studies in critically 
ill patients after cardiac surgery demon-
strated that at least two routes of cardiac 
autonomic modulation pave the way to AF, 
( - ) whereby a landmark study reported 
concomitant vagal withdrawal and sympa-
thetic activation as a mode of perioperative 
AF activation. In sharp contrast, we have 
shown that patients developing AF after 
cardiac surgery, having  been on complete 
chronic beta blockade exhibit different, 
parasympathetically (co)mediated routes 
of cardiac autonomic modulation with 
concomitant parasympathetic and exces-
sive adrenergic activation. ( ) 
PROMOTORS OF AF IN CRITICALLY 
ILL
In critically ill patients with AF we can de-
tect and modify promotors of AF. ( ) The 
most important promotor is adrenergic 
overstimulation (i.e. stress, pain and ino-
tropic support). Other important promot-
ers are myocardial (atrial) stretch (i.e. fluid 
overload, acute mitral regurgitation, mitral 
stenosis, pulmonary embolism), inappro-
priate oxygen delivery to the myocardium 
(i.e. myocardial ischemia, hypovolemia, 
anemia), electrolyte disturbance (i.e. hy-
pokalemia, hypomagnesemia), systemic 
and local inflammation (i.e. after on-pump 
cardiac surgery, sepsis, myo/pericarditis), 
hypothermia, concomitant increased vagal 
activity and intrinsic cardiac autonomous 
system hyperreactivity and endocrine dis-
orders (i.e. hyperthyroidism, pheochro-
mocytoma).
ADRENERGIC OVERLOAD
A recently published review explores the 
schizophrenic ‘Jekyll-and-Hyde’ character-
istics of catecholamines in critical illness, 
as they are both necessary for survival 
yet detrimental in excess. ( ) A hyperadr-
energic state is responsible for the revers-
ible myocardial depression seen in both 
phaeochromocytoma crisis ( ) and the 
stress-related (“broken heart”, Takotsubo) 
cardiomyopathy. ( ) Adrenergic overstimu-
lation is associated with a poor prognosis 
in acute coronary syndromes, heart failure, 
liver cirrhosis and acute cerebrovascular 
disease. ( - )
Despite association with adverse out-
comes, adrenergic agonists remain the 
cornerstone of cardiovascular support. 
Norepinephrine is the current recom-
mended first-line agent for low vascular 
resistance states, while dobutamine is rec-
ommended for myocardial dysfunction. 
(  ) Epinephrine has both inotropic and 
pressor properties that can be used as an 
alternative to either. ( ) It is likely that these 
exogenous catecholamines will add further 
to the endogenous stress response, there-
fore increasing total adrenergic stress. (21) 
It was shown that dobutamine administra-
tion was independently associated with in-
creased mortality in acute heart failure and 
after cardiac surgery. ( , ) High levels of cat-
echolamines as well as a persistently high 
heart rate predict poor patient outcomes 
in sepsis. ( , ) While high catecholamine 
levels could simply be a marker of disease 
severity, they may also be a perpetrator of 
further organ dysfunction. (21)  Increasing 
catecholamine doses were associated with 
increasing mortality, independent of ef-
fects on blood pressure. ( )  
One of the steps towards reducing adren-
ergic overload is to not necessarily target 
“normal” or “supranormal” haemodynam-
ic values. (21) While too low a blood pres-
sure or cardiac output may compromise 
tissue perfusion and oxygenation, neither 
increasing blood pressure >65  mmHg ( ) 
nor targeting “supranormal” values of car-
diac output ( ) translated into an overall 
survival benefit. Previously normotensive 
patients trended to worse outcomes when 
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a higher blood pressure was targeted. (34) 
Unrecognized diastolic dysfunction may 
be also compromised further by the use of 
catecholamines. ( ) 
PHARMACOGENETICS
In some patients, an inappropriate high 
ventricular rate is noticed despite a rela-
tively low dose of inotropic or vasopressor 
dose after adequate volume resuscitation. 
Pharmacogenetics can provide an answer 
to this diversity. ( ) Twelve single-nucle-
otide polymorphisms have been identi-
fied in the β1-AR, but only 2 of these are 
thought to be clinically relevant. At posi-
tion 389, the glycine nucleotide in the G-
protein coupling domain can be substitut-
ed for arginine. ( ) This is again a function 
of polymorphism, resulting in increased 
adenylate cyclase activity. The Arg/Arg 
genotype is associated with increased sen-
sitivity of the β1-AR to noradrenaline, ( ) a 
3- to 4-fold increase in signal transduction 
and an increase in the number of consti-
tutionally active receptors compared with 
the Arg/Gly or Gly/Gly genotypes. ( ) The 
other important β1-AR polymorphism 
is at position 49 and is thought to have a 
modulating role in adenylate cyclase ac-
tivity. (39) The gain of function Arg/Arg 
polymorphism is important because high-
er adrenergic activity has been shown to 
increase the likelihood of AF induction in 
a dose-dependent manner. ( ) Bucindolol, 
a competitive antagonist of the β1-AR, fa-
cilitates the inactivation of constitutionally 
active receptors (inverse agonism), and de-
creases levels of noradrenaline. Bucindolol 
prevented new-onset AF in patients with 
heart failure with reduced ejection fraction 
in 74% of patients with the Arg/Arg geno-
type, but had no effect in those patients 
with the Gly/Gly genotype. ( ) The sub-
study found that all-cause and cardiovas-
cular mortality, as well as cardiovascular 
and heart failure hospitalizations were sig-
nificantly reduced in patients with the Arg/
Arg genotype, but not glycine carriers. ( ) 
The enhanced adrenergic signaling in the 
Arg/ Arg genotype may render it more sus-
ceptible to β blocking drugs’ sympatholytic 
actions, thereby preventing the induction 
of AF that might normally occur in these 
patients. Interestingly, the loss of function 
glycine 389 polymorphism is associated 
with a significantly better response to rate-
controlling therapies in patients with AF. ( 
) This may be explained because the rate-
control therapies can work synergistically 
with the attenuated β1-adrenergic cascade 
caused by this genotype.
β1-AR polymorphisms could also influ-
ence the efficacy of amiodarone because it 
possesses antiadrenergic effects. ( )
Β-ANTAGONISTS AND DECATECHO-
LAMINIZATION IN THE CRITICALLY 
ILL
According to current guidelines, 
β-adrenergic blockade is the first line of 
treatment of AF in patients with preserved 
left ventricular function, and β-adrenergic 
blockade should also be considered in pa-
tients with decreased left ventricular func-
tion. ( , ) Landiolol, an ultra- short acting 
β-antagonist, seems to be fast, effective and 
safe in converting AF to sinus rhythm in 
post- operative cardiac surgery patients. ( 
) At a low dose, landiolol facilitates a high 
rate of conversion to sinus rhythm (69%) 
in patients with sepsis and supraventricu-
lar tachycardia without haemodynamic 
deterioration. ( )
In a poor prognosis subset of patients with 
septic shock, i.e. requiring high doses of 
catecholamines after 24h and with concur-
rent tachycardia, esmolol demonstrated 
significant reductions in mortality, time 
on vasopressors, and renal and myocardial 
injury compared to the control group. ( ) 
Further studies should confirm the data 
from this revolutionary idea. In our opin-
ion, the extreme caution in patient selec-
tion based on echocardiografically deter-
mined preserved systolic and impaired 
diastolic left/right ventricular function 
and very low initial dose of ultra-selective 
β1-blocker is necessary not to induce harm 
to the critically ill septic patient. ( )  In the 
future, it will be probably important even 
to determine pharmacogenetic profile of 
β-AR in these patients. 
Critical illness and management in a criti-
cal care unit are characterised by a severe 
and abnormally prolonged stressor re-
sponse, which may become maladaptive.
(21) Given this premise, attenuation of 
an excessive adrenergic component of the 
stress reaction is a tempting therapeutic 
option during sepsis and other critically ill 
states. 
Titration of β-blocker dosing to a target 
heart rate appears feasible without compro-
mising haemodynamics in most patients; 
stroke volume usually increases while 
catecholamine requirements decrease. ( ) 
Possible mechanisms include: improved 
ventricular filling and ventricular-arterial 
coupling; restoration of adrenergic recep-
tor density, which may have been reduced 
by excessive catecholamine stimulation; ( , 
) and a decrease in the systemic inflamma-
tory response. ( )
Patient selection and close monitoring are 
likely to be crucial in this setting because of 
the risk of worsening myocardial dysfunc-
tion. (21)
The pharmacogenetic properties of 
β-blockers and an individual approach are, 
therefore, an important area for further 
research to further understand which pa-
tients will benefit from both existing and 
novel therapies for AF and supraventricu-
lar tachycardia in the critically ill.
METABOLIC EFFECTS OF 
Β-BLOCKERS
The majority of the critically ill have 
high resting energy expenditure (REE), 
this is especially true for patients with 
burns, after severe trauma and in sepsis. 
( ) Also patients with heart failure, who 
are not cachectic, have high REE. ( , )  It 
has been demonstrated that selective and 
nonselective β-blockers reduce the REE. ( 
) Nonselective β-blockers appear to shift 
total body substrate use from fatty-acid 
to glucose oxidation. (58, , ) As less oxy-
gen is needed for the oxidation of glucose 
than for the oxidation of fatty acids, ( ) 
this as a favorable effect on myocardial 
oxygen demand in heart failure. The mo-
lecular mechanisms by which nonselective 
β-blockers promote glucose oxidation are 
not known, but it has been demonstrated 
in mice that the receptor NOR-1, which is 
a target of β-adrenergic signaling, regulates 
expression of genes that encode proteins 
that control oxidative metabolism, such 
as PGC-1α, lipin-1α, FOXO1, and the en-
zyme pyruvate dehydrogenase kinase type 
4 (PDK4). ( ) This last, PDK4, is an isoform 
of PDK that is directly involved in the reg-
ulation of the entry of glycolysis products 
into oxidative metabolism. This is also one 
possible explanation why only the nonse-
lective β-blockers appear to influence the 
shift of metabolism to glucose oxidation 
– because they do not only interact with 
the target β1-adrenergic receptors. Clini-
cal studies confirmed the metabolic effects 
of non-selective blockers: propranolol 
reduced hypermetabolism in burs which 
could be prolonged up to 2 years; and 
carvedilol attenuated the development and 
promoted a partial reversal of cachexia in 
patients with severe chronic heart failure, 
supporting a role for prolonged sympa-
thetic activation in the genesis of weight 
loss. ( , )
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CONCLUSIONS 
Catecholamine administration is useful 
and even life-saving for short-term res-
toration of tissue perfusion or correction 
of life threatening hypotension. However, 
catecholamines are poisonous when given 
in excess, causing regional ischemia, trig-
gering arrhythmia and promoting systemic 
inflammation. Individual titration of short-
acting selective β-1 blockers seems to be 
a promising approach to supraventricular 
tachycardia and to a maladaptive response 
to sepsis, especially in the hemodynami-
cally stable phase of disease. On the other 
hand, non-selective β-blockers are impor-
tant regulators of whole body metabolism, 
capable of reducing resting energy expend-
iture, attenuating the development and 
promoting partial reversal of cachexia.   
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